Lamotrigine chewable tablets, marketed by GlaxoSmithKline as Lamictal chewable dispersible tablets, is a prescription pharmaceutical product used in treating seizures.
Taro previously filed a ‘Paragraph IV’ certification challenging GlaxoSmithKline’s patent protection on Lamictal.